1. Home
  2. ALT vs DHIL Comparison

ALT vs DHIL Comparison

Compare ALT & DHIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • DHIL
  • Stock Information
  • Founded
  • ALT 1997
  • DHIL 1990
  • Country
  • ALT United States
  • DHIL United States
  • Employees
  • ALT N/A
  • DHIL N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • DHIL Investment Managers
  • Sector
  • ALT Health Care
  • DHIL Finance
  • Exchange
  • ALT Nasdaq
  • DHIL Nasdaq
  • Market Cap
  • ALT 327.4M
  • DHIL 392.1M
  • IPO Year
  • ALT N/A
  • DHIL 1995
  • Fundamental
  • Price
  • ALT $3.59
  • DHIL $143.00
  • Analyst Decision
  • ALT Strong Buy
  • DHIL
  • Analyst Count
  • ALT 6
  • DHIL 0
  • Target Price
  • ALT $17.40
  • DHIL N/A
  • AVG Volume (30 Days)
  • ALT 2.4M
  • DHIL 25.1K
  • Earning Date
  • ALT 11-11-2025
  • DHIL 11-03-2025
  • Dividend Yield
  • ALT N/A
  • DHIL 4.27%
  • EPS Growth
  • ALT N/A
  • DHIL 21.42
  • EPS
  • ALT N/A
  • DHIL 17.58
  • Revenue
  • ALT $20,000.00
  • DHIL $151,281,009.00
  • Revenue This Year
  • ALT N/A
  • DHIL N/A
  • Revenue Next Year
  • ALT $761,880.20
  • DHIL N/A
  • P/E Ratio
  • ALT N/A
  • DHIL $8.07
  • Revenue Growth
  • ALT N/A
  • DHIL 6.29
  • 52 Week Low
  • ALT $2.90
  • DHIL $122.32
  • 52 Week High
  • ALT $11.16
  • DHIL $173.25
  • Technical
  • Relative Strength Index (RSI)
  • ALT 45.32
  • DHIL 53.23
  • Support Level
  • ALT $3.54
  • DHIL $139.13
  • Resistance Level
  • ALT $3.72
  • DHIL $145.76
  • Average True Range (ATR)
  • ALT 0.16
  • DHIL 2.03
  • MACD
  • ALT 0.02
  • DHIL -7.72
  • Stochastic Oscillator
  • ALT 21.87
  • DHIL 95.92

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About DHIL Diamond Hill Investment Group Inc.

Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.

Share on Social Networks: